Financial Analysis: Dynavax Technologies (NASDAQ:DVAX) versus Mawson Infrastructure Group (OTCMKTS:WIZP)

Dynavax Technologies (NASDAQ:DVAX) and Mawson Infrastructure Group (OTCMKTS:WIZP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

97.0% of Dynavax Technologies shares are held by institutional investors. 3.0% of Dynavax Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Dynavax Technologies and Mawson Infrastructure Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynavax Technologies	0	1	2	0	2.67
Mawson Infrastructure Group	0	0	0	0	0.00

Dynavax Technologies currently has a consensus price target of $22.00, indicating a potential upside of 76.99%. Given Dynavax Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe Dynavax Technologies is more favorable than Mawson Infrastructure Group.

Risk and Volatility

Dynavax Technologies has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Mawson Infrastructure Group has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Profitability

This table compares Dynavax Technologies and Mawson Infrastructure Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dynavax Technologies	6.88%	2.76%	1.73%
Mawson Infrastructure Group	N/A	N/A	-85.32%

Earnings and Valuation

This table compares Dynavax Technologies and Mawson Infrastructure Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynavax Technologies	$232.28 million	7.01	-$6.39 million	$0.11	113.01
Mawson Infrastructure Group	N/A	N/A	-$3.45 million	($0.33)	-5.88

Mawson Infrastructure Group has lower revenue, but higher earnings than Dynavax Technologies. Mawson Infrastructure Group is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Dynavax Technologies beats Mawson Infrastructure Group on 11 of the 13 factors compared between the two stocks.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

About Mawson Infrastructure Group

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia.